Premium
Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions
Author(s) -
Cho Mar K,
Eimoto T,
Tateyama H,
Arai Y,
Fujiyoshi Y,
Hamaguchi M
Publication year - 2006
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2005.02325.x
Subject(s) - matrix metalloproteinase , follicular phase , pathology , stroma , adenoma , immunohistochemistry , stromal cell , thyroid carcinoma , biology , thyroid , medicine , cancer research
Aims : To examine expression of matrix metalloproteinases (MMPs) and related proteins in follicular thyroid lesions (FTLs) and to determine their usefulness for differential diagnosis of FTLs, particularly between minimally invasive carcinoma and adenoma. Methods and results : Six widely invasive follicular carcinomas (WIFCs), 15 minimally invasive follicular carcinomas (MIFCs), 19 follicular adenomas (FAs) and 10 adenomatous goitres (AGs) were analysed immunohistochemically for MMP‐1, MMP‐2, MMP‐7, MMP‐9, membrane‐type 1‐MMP (MT1‐MMP) and tissue inhibitor of matrix metalloproteinase‐2 (TIMP‐2). MMP‐1 was positive in all FTLs. MMP‐2 and MMP‐7 were positive in more than 80% of WIFC and MIFC cases, whereas they were negative in all FA and AG cases except one MMP‐2+ FA ( P < 0.001). MMP‐9 stained positive significantly more in MIFC than FA or AG cases ( P < 0.05, respectively). The positivity of MT1‐MMP and TIMP‐2 was different among some of the FTLs, but with no significant difference between MIFC and FA cases. In‐situ hybridization of MMP‐2 and MMP‐7 mRNA in selected cases demonstrated the expression of these enzymes in the tumour cells as well as in some stromal cells. Conclusions : Our results confirm MMP expression mainly in malignant FTLs and suggest that MMP‐2 and MMP‐7 may be useful markers to distinguish MIFC from FA.